Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2017

View Archived Issues

Regen Biopharma enters agreement to optimize NR2F6 modulators

Hope Biosciences gains rights to MERTK/AXL inhibitor from NeoPharm

Biogen completes separation of global hemophilia business and launches Bioverativ

FDA orphan drug status given to CyTIX-DCf 12-GLI for malignant glioma

Increased potency of CB-2679d may allow subcutaneous dosing for hemophilia B

FDA grants accelerated approval to Opdivo in metastatic urothelial carcinoma

FDA grants authorization for Abbott RealTime ZIKA test to detect Zika virus using whole blood

Vividion Therapeutics launches with novel drug discovery platform

Protagen and NCI collaborate to provide insight into immuno-oncology

Repatha cardiovascular outcomes study and cognition function study meet primary endpoints

Summit Therapeutics outlines phase III program for ridinilazole

Fortress Biotech's Mustang Bio closes private placement financing to support immunotherapy pipeline

Sustained factor IX activity seen with single infusion of SPK-9001 gene therapy

Galapagos begins dosing patients with cystic fibrosis in ALBATROSS study

GenomeDx to perform genomic tumor profiling for Astellas' ENACT study of enzalutamide

Aviragen reports topline data from phase IIa study of BTA-585 for RSV

Soligenix's SGX-301 granted PIM designation in U.K.

FDA gives orphan drug designation to Lysogene's gene therapy candidate for GM1 gangliosidosis

Glecaprevir/pibrentasvir NDA granted priority review by FDA

Guangzhou Maxinovel Pharmaceuticals divulges novel tyrosine kinase inhibitors

Sunshine Lake Pharma patents orexin receptor antagonists

Bayer discloses new mutant IDH1 inhibitors

Ono Pharmaceutical discovers prostanoid EP2 receptor agonists

Astellas Pharma offers overview of third quarter of fiscal 2016

Pharmakea presents novel lysyl oxidase homolog 2 inhibitors

Daiichi Sankyo reports key milestones of third quarter of fiscal 2016

Promising MOD-5014 results in a phase I/IIa clinical trial in hemophilia patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...